TIAA CREF Investment Management LLC Raises Position in Syndax Pharmaceuticals, Inc. (SNDX)

TIAA CREF Investment Management LLC boosted its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 115.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 49,484 shares of the company’s stock after acquiring an additional 26,560 shares during the period. TIAA CREF Investment Management LLC owned 0.27% of Syndax Pharmaceuticals worth $691,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Jennison Associates LLC acquired a new stake in Syndax Pharmaceuticals in the 2nd quarter valued at about $13,325,000. JPMorgan Chase & Co. grew its stake in Syndax Pharmaceuticals by 11,266.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 439,070 shares of the company’s stock valued at $6,134,000 after acquiring an additional 435,207 shares during the last quarter. Sphera Funds Management LTD. grew its stake in Syndax Pharmaceuticals by 78.2% in the 2nd quarter. Sphera Funds Management LTD. now owns 296,310 shares of the company’s stock valued at $4,139,000 after acquiring an additional 130,000 shares during the last quarter. Morgan Stanley grew its stake in Syndax Pharmaceuticals by 209.0% in the 1st quarter. Morgan Stanley now owns 119,987 shares of the company’s stock valued at $1,646,000 after acquiring an additional 81,159 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Syndax Pharmaceuticals by 10.5% in the 1st quarter. Geode Capital Management LLC now owns 98,962 shares of the company’s stock valued at $1,357,000 after acquiring an additional 9,410 shares during the last quarter. 64.31% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “TIAA CREF Investment Management LLC Raises Position in Syndax Pharmaceuticals, Inc. (SNDX)” was posted by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://weekherald.com/2017/11/15/tiaa-cref-investment-management-llc-raises-position-in-syndax-pharmaceuticals-inc-sndx.html.

Syndax Pharmaceuticals, Inc. (SNDX) opened at $8.37 on Wednesday. Syndax Pharmaceuticals, Inc. has a 1-year low of $6.31 and a 1-year high of $15.70.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Tuesday, November 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.80) by $0.12. The company had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.30 million. Syndax Pharmaceuticals had a negative net margin of 4,304.34% and a negative return on equity of 57.90%. The firm’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.84) EPS. research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.03 earnings per share for the current fiscal year.

A number of equities research analysts recently commented on SNDX shares. Zacks Investment Research cut shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. Citigroup Inc. set a $20.00 price objective on shares of Syndax Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 11th. Nomura lowered their price objective on shares of Syndax Pharmaceuticals from $27.00 to $22.00 and set a “buy” rating on the stock in a research note on Friday, August 11th. Oppenheimer Holdings, Inc. upped their target price on shares of Syndax Pharmaceuticals to $29.00 and gave the company an “outperform” rating in a report on Friday, August 11th. Finally, Instinet restated a “buy” rating and issued a $22.00 target price (down from $27.00) on shares of Syndax Pharmaceuticals in a report on Monday, August 14th. Two research analysts have rated the stock with a sell rating and eight have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $23.13.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.

Want to see what other hedge funds are holding SNDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX).

Institutional Ownership by Quarter for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply